Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

CURENETICS

Innovative cancer med-tech, leveraging genomic, histological and clinico-demographic data to predict patient’s responses to cancer immunotherapy.

£ 110,000
0 Days left

31% of minimum goal raised

Seeking
Lead investor:

Minimum Target

£ 350,000

Minimum investment amount

£ 10,000

Maximum Target

£ 550,000

Maximum investment amount

£ 550,000

Investment Opportunity

Curenetics aims to optimise cancer treatment delivery by improving the prediction of immunotherapy treatment response, toxicity, and resistance through data-driven approaches. Our goal is to leverage clinical, genomic and histological biomarker data to develop predictive models of response to immunotherapy for cancers even before commencing treatment. We are backed by several clinical partners and advisors who work alongside us to provide us guidance and support to ensure our product has a good market fit. Our core team is made up of our CEO, CTO/data scientist, COO/AI engineer Operational and Clinical Lead and Immunologist who are working tirelessly to turn our mission into a reality

LIVE PITCHING

Curenetics at Angels Den's HealthTech Pitching Event

You have to log in or register to see this information.
THE IDEA
Products & Services

We will develop a fully tested and validated decision support tool for cancer immunotherapy response prediction for use by clinicians and allied medical professionals. The support tool will employ state-of-the-art machine learning methodologies for pre-processing of high dimensional genomic and imaging data, for the discovery of patterns or motifs related to cancer response and treatment toxicity. This tool will be offered as software as medical device(SaMD). In addition to the machine learning predictive tools, a user-friendly graphical user interface for the developed software tools will be made according to the specifications of existing medical software platforms and user specifications

Problem Solved

The tool will aid clinicians in deciding the best immunotherapy treatment strategy for cancer patients. This will lead to better patient selection, improved patient survival, reduced treatment toxicity and value for money for healthcare providers. This will usher in the next level of personalised cancer care.

Revenue Model

Our business model is software as a service or medical device (SaaS/SaMD) licensed to hospitals, healthcare providers and healthcare insurers around the world. We are currently focusing on cancer immunotherapy applications which is a huge market that is predicted to be worth over £300B by 2030. Beyond cancer, we will enter other markets such as gastroenterology, rheumatology and ophthalmology where immunotherapy treatment are increasingly used.

Exit Strategy
You have to log in or register to see this information.

The Idea

Products & Services

We will develop a fully tested and validated decision support tool for cancer immunotherapy response prediction for use by clinicians and allied medical professionals. The support tool will employ state-of-the-art machine learning methodologies for pre-processing of high dimensional genomic and imaging data, for the discovery of patterns or motifs related to cancer response and treatment toxicity. This tool will be offered as software as medical device(SaMD). In addition to the machine learning predictive tools, a user-friendly graphical user interface for the developed software tools will be made according to the specifications of existing medical software platforms and user specifications

Problem Solved

The tool will aid clinicians in deciding the best immunotherapy treatment strategy for cancer patients. This will lead to better patient selection, improved patient survival, reduced treatment toxicity and value for money for healthcare providers. This will usher in the next level of personalised cancer care.

Revenue Model

Our business model is software as a service or medical device (SaaS/SaMD) licensed to hospitals, healthcare providers and healthcare insurers around the world. We are currently focusing on cancer immunotherapy applications which is a huge market that is predicted to be worth over £300B by 2030. Beyond cancer, we will enter other markets such as gastroenterology, rheumatology and ophthalmology where immunotherapy treatment are increasingly used.

Exit Strategy
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.

Location

HORNCHURCH

Gallery